KPC Pharmaceuticals,Inc.

SHSE:600422 Stok Raporu

Piyasa değeri: CN¥11.4b

KPC PharmaceuticalsInc Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 4/6

KPC PharmaceuticalsInc's earnings have been declining at an average annual rate of -2.4%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been declining at an average rate of 0.8% per year. KPC PharmaceuticalsInc's return on equity is 7.9%, and it has net margins of 5.9%.

Anahtar bilgiler

-2.4%

Kazanç büyüme oranı

-2.1%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi10.9%
Gelir büyüme oranı-0.8%
Özkaynak getirisi7.9%
Net Marj5.9%
Son Kazanç Güncellemesi30 Sep 2024

Yakın geçmiş performans güncellemeleri

KPC PharmaceuticalsInc's (SHSE:600422) Profits May Not Reveal Underlying Issues

Mar 28
KPC PharmaceuticalsInc's (SHSE:600422) Profits May Not Reveal Underlying Issues

Recent updates

Is KPC Pharmaceuticals,Inc. (SHSE:600422) Trading At A 42% Discount?

Sep 30
Is KPC Pharmaceuticals,Inc. (SHSE:600422) Trading At A 42% Discount?

These 4 Measures Indicate That KPC PharmaceuticalsInc (SHSE:600422) Is Using Debt Safely

Sep 11
These 4 Measures Indicate That KPC PharmaceuticalsInc (SHSE:600422) Is Using Debt Safely

KPC PharmaceuticalsInc (SHSE:600422) Will Pay A Larger Dividend Than Last Year At CN¥0.20

Jul 25
KPC PharmaceuticalsInc (SHSE:600422) Will Pay A Larger Dividend Than Last Year At CN¥0.20

Investors Still Waiting For A Pull Back In KPC Pharmaceuticals,Inc (SHSE:600422)

Jun 25
Investors Still Waiting For A Pull Back In KPC Pharmaceuticals,Inc (SHSE:600422)

We Think KPC PharmaceuticalsInc (SHSE:600422) Can Stay On Top Of Its Debt

Jun 04
We Think KPC PharmaceuticalsInc (SHSE:600422) Can Stay On Top Of Its Debt

KPC PharmaceuticalsInc's (SHSE:600422) Profits May Not Reveal Underlying Issues

Mar 28
KPC PharmaceuticalsInc's (SHSE:600422) Profits May Not Reveal Underlying Issues

Gelir ve Gider Dağılımı

KPC PharmaceuticalsInc nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

SHSE:600422 Gelir, gider ve kazançlar (CNY Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Sep 247,5504462,47488
30 Jun 247,4874512,57579
31 Mar 247,6464322,70572
31 Dec 237,7034452,79171
30 Sep 237,7003972,73739
30 Jun 237,8253902,81546
31 Mar 237,8284002,85257
31 Dec 228,2823832,85170
30 Sep 228,4194462,865102
30 Jun 228,3883922,825108
31 Mar 228,7224272,821104
31 Dec 218,2545082,815101
30 Sep 218,3215402,806140
30 Jun 218,3865642,874139
31 Mar 218,0455602,834145
01 Jan 217,7174572,672128
30 Sep 207,7794452,952103
30 Jun 207,7884442,99093
31 Mar 207,9104433,09479
31 Dec 198,1204543,33784
30 Sep 197,8174293,22677
30 Jun 197,4733903,15983
31 Mar 197,2373563,06277
31 Dec 187,1023363,00083
30 Sep 186,7973162,84270
30 Jun 186,5072952,64190
31 Mar 186,2803182,37983
31 Dec 175,8523302,13063
30 Sep 175,6373571,93640
30 Jun 175,3303741,7460
31 Mar 175,1704161,6180
31 Dec 165,1014071,5190
30 Sep 165,1614401,2950
30 Jun 165,2274481,3040
31 Mar 165,0494331,2240
31 Dec 154,9164211,1770
30 Sep 154,5884041,0760
30 Jun 154,4563679830
31 Mar 154,3613089900
31 Dec 144,3162899310
30 Sep 144,0382649040
30 Jun 143,8602588300
31 Mar 143,6682437250
31 Dec 133,5842327280

Kaliteli Kazançlar: 600422 has high quality earnings.

Büyüyen Kar Marjı: 600422's current net profit margins (5.9%) are higher than last year (5.1%).

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 600422's earnings have declined by 2.4% per year over the past 5 years.

Büyüme Hızlandırma: 600422's earnings growth over the past year (12.5%) exceeds its 5-year average (-2.4% per year).

Kazançlar vs. Sektör: 600422 earnings growth over the past year (12.5%) exceeded the Pharmaceuticals industry -1.2%.

Özkaynak Getirisi

Yüksek ROE: 600422's Return on Equity (7.9%) is considered low.

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y